Grifols asset sell-off paves way for $4bn US blood products deal
This article was originally published in Clinica
Executive Summary
Spanish blood products and diagnostics group Grifols looks set to become the world’s number-three player in the blood plasma products market, after US antitrust authorities gave a tentative nod this week for the company to go ahead with its proposed $4bn acquisition of US firm Talecris Biotherapeutics.